Siemens wins EUA for semiquantitative SARS-CoV-2 antibody test

By staff writers

August 5, 2020 -- Siemens Healthineers has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COV2G semiquantitative SARS-CoV-2 immunoglobulin G (IgG) antibody test.

The antibody test is the first with a semiquantitative claim to receive an EUA from the FDA, according to Siemens. COV2G offers both a positive or negative result for IgG antibodies and reports a numerical result expressed as index value. It has been shown to offer 100% sensitivity and 99.9% specificity, Siemens said.

The test has also received the CE Mark and is now broadly available around the world.

Siemens revenue falls 7% in third quarter
Siemens Healthineers saw its revenue fall 7% in the company's third fiscal quarter due to the impact of the COVID-19 pandemic. The company saw a single-digit...
Siemens wins clearance in Canada for SARS-CoV-2 test
Siemens Healthineers has received authorization from Health Canada for its Fast Track Diagnostics SARS-CoV-2 Assay test kit.
Siemens coronavirus antibody test beats rivals in Public Health England study
A Siemens SARS-CoV-2 antibody test outperformed immunoassays from other, major manufacturers in a large study conducted by the U.K. government and published...
FDA authorizes Siemens' SARS-CoV-2 total antibody test
Siemens Healthineers has received an emergency use authorization from the U.S. Food and Drug Administration for its test to identify SARS-CoV-2 immunoglobulin...
Siemens ships COVID-19 total antibody tests worldwide, wins EUA for molecular test
Siemens Healthineers has begun shipping its total COVID-19 antibody test kits worldwide and has also received emergency use authorization (EUA) from the...

Copyright © 2020

Last Updated ls 8/5/2020 9:07:42 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current